Novel__O research__O by__O Proudman__B-MISC and__O colleagues__O at__O the__O UoL__B-ORG has__O significantly__O improved__O the__O way__O a__O potentially__O devastating__O equine__O health__O risk__O is__O diagnosed,__O managed__O and__O treated.__O
This__O research__O into__O equine__O colic__O has__O resulted__O in__O impacts__O both__O domestically__O and__O internationally__O and__O includes__O (i)__O improvements__O to__O animal__O health__O by__O way__O of__O diagnostic__O testing,__O updated__O healthcare__O guidelines,__O and__O public__O and__O industry__O awareness__O activities__O promoting__O the__O benefits__O of__O anthelmintic__O use,__O and__O (ii)__O generation__O of__O an__O increased__O income__O stream__O for__O the__O animal__O health__O industry__O and__O pharmaceutical__O companies__O by__O proving__O the__O clear__O benefits__O of__O using__O anti-tapeworm__O drugs__O for__O a__O major__O equine__O problem.__O
Beneficiaries__O are__O horses__O and__O their__O owners__O through__O improved__O welfare;__O veterinarians__O and__O testing__O laboratories__O through__O an__O increased__O range__O of__O services__O for__O tapeworm__O infection__O detection;__O and__O treatment__O and__O pharmaceutical__O companies__O through__O additional__O products__O and__O sales.__O
UoL__O research__O linking__O equine__O colic__O to__O tapeworm__O exposure__O has__O led__O to__O the__O widespread__O use__O of__O anti-__O tapeworm__O therapies__O to__O treat__O the__O two__O described__O forms__O of__O colic.__O
This__O has__O primarily__O manifested__O as__O worldwide__O changes__O to__O recommended__O protocols__O for__O treating__O equine__O colic__O effectively.__O
As__O a__O result,__O Proudman's__B-MISC research__O findings__O and__O conclusions__O have__O been__O incorporated__O (2010__O -__O 2012)__O into__O equine__O healthcare__O guidelines__O and__O widely__O adopted__O in__O the__O UK__B-LOC and__O internationally.__O
Diagnosis__O and__O preventative__O treatment__O The__O development__O by__O the__O UoL__O of__O a__O serological__O test__O for__O tapeworm__O infection__O has__O given__O veterinary__O surgeons__O and__O researchers__O a__O risk__O assessment__O tool__O and__O which__O has__O become__O a__O key__O diagnostic__O assay__O that__O is__O in__O routine__O use__O in__O equine__O medicine.__O
The__O University__B-ORG of__I-ORG Liverpool__I-ORG operates__O a__O commercial__O diagnostic__O service__O for__O the__O test__O (branded__O as__O "Diagnosteq").__O
This__O service__O is__O widely__O used__O by__O vets__O in__O the__O UK__B-LOC and__O Europe.__B-LOC
During__O the__O period__O 2008__O to__O 2012,__O the__O service__O tested__O 19,887__O samples__O for__O clinicians__O to__O guide__O worm__O control__O programmes.__O
The__O serological__O test__O for__O equine__O tapeworm__O infection__O is__O unique__O to__O this__O laboratory.__O
The__O 'Diagnosteq'__B-MISC service__O has__O also__O undertaken__O serological__O testing__O for__O epidemiological__O research__O purposes__O on__O samples__O from__O 15__O different__O countries,__O including__O the__O USA,__B-LOC Canada,__I-LOC Australia,__I-LOC Japan,__I-LOC France,__I-LOC Germany,__I-LOC Sweden,__I-LOC Norway,__I-LOC The__I-LOC Netherlands__I-LOC and__O Italy.__B-LOC
Proudman's__O research__O showed__O a__O clear__O reduction__O in__O colic__O risk__O when__O anti-tapeworm__O anthelmintics__O were__O used.__O
The__O launch__O of__O anti-tapeworm__O anthelmintics__O has__O been__O accompanied__O by__O extensive__O public__O engagement__O activities,__O including__O websites__O [e.g.__O
14]__O and__O CPD__O courses__O for__O equine__O surgeons__O [15]__O to__O raise__O public__O and__O industry__O awareness__O of__O the__O value__O of__O their__O usage__O to__O prevent__O life__O threatening__O colic__O in__O horses.__O
Awareness__O raising__O The__O importance__O of__O equine__O tapeworm__O control__O is__O now__O embedded__O in__O undergraduate__O veterinary__O curricula,__O CPD__B-ORG programmes__O for__O practising__O veterinary__O surgeons__O and__O training__O of__O lay__O prescribers__O of__O anthelmintic__O drugs__O (Suitably__B-ORG Qualified__I-ORG Persons)__I-ORG [8]__O and__O sources__O of__O professional__O information__O [9].__O
Increased__O awareness__O of__O intestinal__O tapeworms__O as__O a__O risk__O to__O horse__O health,__O plus__O the__O knowledge__O and__O products__O to__O implement__O effective__O tapeworm__O control__O is__O now__O widely__O available__O to__O the__O general__O public__O of__O horse__O owners__O [e.g.__O
7,10,11,12].__O
Equine__O anthelmintic__O market__O Recognising__O the__O significance__O of__O Proudman's__B-ORG research__O to__O equine__O healthcare__O programmes,__O several__O international__O animal__O health__O pharmaceutical__O companies__O have__O applied__O for__O marketing__O authorisation__O and__O launched__O anti-tapeworm__O anthelmintics__O for__O use__O in__O horses__O citing__O the__O UoL__B-ORG research__O as__O indicating__O a__O need__O for__O tapeworm__O control__O in__O horses.__O
Veterinary__O sales__O clearly__O indicate__O significant__O growth__O in__O the__O anti-__O tapeworm__O sector__O of__O the__O equine__O anthelmintic__O market.__O
During__O the__O impact__O qualifying__O period__O (2008__O -__O 2012),__O five__O pharmaceutical__O companies__O (Elanco,__B-ORG Intervet,__I-ORG Merial,__B-PER Pfizer__I-PER and__O Virbac)__B-LOC were__O marketing__O between__O 15__O -__O 17__O anti-tapeworm__O products__O with__O &#163;9.7m__O sales__O in__O 2010.__O
This__O compares__O to__O a__O market__O of__O 5__O products__O produced__O by__O 2__O companies__O and__O annual__O sales__O of__O just__O &#163;3.9m__O in__O 2001;__O a__O 250%__O increase__O in__O sales.__O
Veterinary__O practise__O sales__O represent__O only__O 15-20%__O of__O total__O veterinary__O anthelmintic__O sales,__O the__O remainder__O being__O sold__O directly__O to__O horse-owners.__O
Some__O companies__O use__O serological__O testing__O for__O risk__O screening__O [13].__O
